Garheng Kong - 04 Jun 2026 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Reporting relationship: Director
Issuer ticker: XERS
Reported as of: 04 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2026, 18:39:36 UTC
Prior SEC filing: 13 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Beth Hecht, Attorney-in-Fact

Key filing fact

Garheng Kong filed Form 4 for Xeris Biopharma Holdings, Inc. (XERS) on 05 Jun 2026.

Key facts

This page summarizes Garheng Kong's Form 4 filing for Xeris Biopharma Holdings, Inc. (XERS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2026, 18:39.

Change

Previous filing in this sequence was filed on 13 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001435183 Primary reporting owner

Kong Garheng

Relationship: Director
Address: C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO
Signature: /s/ Beth Hecht, Attorney-in-Fact
Signature date: 05 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XERS transaction

Common Stock

Award

Transaction value
Shares: +24,193
Change %: +11%
Price: $0.000000^*
Shares after: 238,337
Date: 04 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XERS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +32,996
Change %
Price: $6.15^*
Shares after: 32,996
Date: 04 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,996
Exercise price: $6.15
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

Footnote F2

These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.